Kimyrsa Side Effects

Generic name: oritavancin

Medically reviewed by Drugs.com. Last updated on Jun 25, 2024.

Note: This document provides detailed information about Kimyrsa.

Applies to oritavancin: intravenous powder for solution Side Effects associated with oritavancin. Some dosage forms listed on this page may not apply specifically to the brand name Kimyrsa.

Applies to oritavancin: intravenous powder for solution.

Precautions

It is very important that your doctor will check your progress closely while you are receiving this medicine to make sure it is working properly. Blood tests may be needed to check for unwanted effects.

Using this medicine together with warfarin may increase the risk of bleeding. If you use warfarin, tell your doctor right away if you have bleeding gums, dizziness, nosebleeds, red or black, tarry stools, red or dark brown urine, trouble breathing, or are coughing up blood.

Before you have any medical tests, tell the medical doctor in charge that you are using this medicine. The results of some tests may be affected by this medicine.

You should not receive a heparin injection if you have received oritavancin (the active ingredient contained in Kimyrsa) within the past 120 hours (5 days). Receiving these medicines together may affect the results of some tests.

This medicine may cause serious allergic reactions, including anaphylaxis, which can be life-threatening and requires immediate medical attention. Tell your doctor right away if you have a rash, itching, trouble breathing, trouble swallowing, or any swelling of your hands, face, or mouth with this medicine.

This medicine may cause infusion-related reactions that can be life-threatening and require immediate medical attention. Tell your doctor right away if you have a cough, difficulty with swallowing, dizziness, a fast heartbeat, trouble breathing, swelling in your face or hands, a fever, chills, itching or hives, or a feeling of warmth or redness on your upper body with this medicine.

This medicine may cause diarrhea, and in some cases it can be severe. It may also occur 2 months or more after you stop using this medicine. Do not take any medicine to treat diarrhea without checking with your doctor. If mild diarrhea continues or gets worse or you have questions, check with your doctor.

Tell your doctor right away if you have bone pain. This may be a symptom of a bone infection (osteomyelitis).

Do not take other medicines unless they have been discussed with your doctor. This includes prescription or nonprescription (over-the-counter [OTC]) medicines and herbal or vitamin supplements.

Serious side effects of Kimyrsa

Along with its needed effects, oritavancin may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking oritavancin:

Other side effects of Kimyrsa

Some side effects of oritavancin may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

For healthcare professionals

Applies to oritavancin: intravenous powder for injection.

General adverse events

In pooled clinical trials, serious side effects were reported in 5.8% of patients treated with this drug (compared to 5.9% treated with vancomycin). Cellulitis was the serious side effect reported most often with both drugs.

This drug was discontinued due to side effects in 3.7% of patients, most often due to cellulitis and osteomyelitis.

The most commonly reported side effects included nausea, headache, vomiting, limb and subcutaneous abscesses, and diarrhea.^[Ref]

Dermatologic

• Common (1% to 10%): Cellulitis, limb abscess, pruritus, rash, subcutaneous abscess, urticaria
• Uncommon (0.1% to 1%): Erythema multiforme, leukocytoclastic vasculitis^[Ref]

Gastrointestinal

• Common (1% to 10%): Constipation, diarrhea, nausea, vomiting
• Frequency not reported: Clostridium difficile associated diarrhea^[Ref]

Hepatic

• Common (1% to 10%): Abnormal liver function tests, increased ALT, increased AST
• Uncommon (0.1% to 1%): Blood bilirubin increased
• Frequency not reported: Increased total bilirubin^[Ref]

Local

• Common (1% to 10%): Infusion site erythema, infusion site phlebitis, infusion site reactions^[Ref]

Infusion site reactions included extravasation, induration, infusion site erythema, infusion site phlebitis, peripheral edema, pruritus, and rash.^[Ref]

Other

• Common (1% to 10%): Extravasation, induration
• Frequency not reported: Infusion related reactions^[Ref]

Cardiovascular

• Common (1% to 10%): Peripheral edema, tachycardia
• Uncommon (0.1% to 1%): Flushing^[Ref]

Nervous system

• Common (1% to 10%): Dizziness, headache^[Ref]

Hematologic

• Common (1% to 10%): Anemia
• Uncommon (0.1% to 1%): Eosinophilia, thrombocytopenia^[Ref]

Musculoskeletal

• Common (1% to 10%): Myalgia
• Uncommon (0.1% to 1%): Osteomyelitis, tenosynovitis^[Ref]

Hypersensitivity

• Uncommon (0.1% to 1%): Angioedema, hypersensitivity/hypersensitivity reactions^[Ref]

Respiratory

• Uncommon (0.1% to 1%): Bronchospasm, wheezing^[Ref]

Metabolic

• Uncommon (0.1% to 1%): Hyperuricemia, hypoglycemia^[Ref]

See also:

Further information

Kimyrsa side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.

Medical Disclaimer